- Lexaria just received another patent for DehydraTECH(TM): this time for the enhanced delivery of antiviral drugs
- This becomes the company’s 25th patent granted worldwide and the 10th granted in the U.S.
- It adds to the company’s growing patent portfolio, which also consists of ~50 pending patents worldwide
- Over the 2022 calendar year, the company seeks to also pursue regulatory and commercial advancement
In 2016, Lexaria Bioscience (NASDAQ: LEXX) received its first United States patent grant and over the years, the company has been aggressive at broadening its patent suite, a move which it has attributed to refining the patent claims via further US provisional and utility patent filings. More patents mean more intellectual property and enhanced ability to pursue regulatory and commercial progress.
As of March 2022, Lexaria had 24 patents, having been granted its latest one in Australia, titled…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.